CMCR Grants Program announces new awards

The Center is pleased to announce two new studies for funding this year, examining 1) the effects of combining THC and cannabigerol on pain, and 2) the impact of CBD on blood pressure and factors related to metabolic syndrome.
Read More.

CMCR studies

Current studies examine the effects of cannabis and cannabinoids on a range of psychiatric, developmental and pain conditions, as well as the impact of use on public safety (e.g., driving). A list of current and past studies can be found here.

CMCR Symposium

Planning is currently underway for the CMCR Symposium for Spring 2021. Please check back for updates. Information on the CMCR symposium series, including archives of previous meetings, can be found here.

  • All
  • Announcements
  • Current Studies
  • Information
  • News
  • Presentations
  • Publications
  • Studies
  • Symposia
  • Default
  • Title
  • Date
  • Random
load more hold SHIFT key to load all load all

PI: Doris Trauner, MD

STUDY LOCATION: University of California, San Diego

PROJECT TITLE: The Effects of Cannabidiol (CBD) on Symptoms of Severe Autism

FUNDING SOURCE: Wholistic Research and Education Foundation

PROJECT TYPE: Clinical Study

STATUS: Enrollment Pending

ABSTRACT:

This clinical trial will examine if and how cannabidiol (CBD), a chemical found in the cannabis plant, provides therapeutic benefit to children with severe autism spectrum disorder (ASD). The trial, funded by a grant from the Ray and Tye Noorda Foundation in partnership with and based on recommendations from the Wholistic Research and Education Foundation.

ASD affects an estimated one in 68 children in the United States, primarily boys. CBD is a major chemical compound found in cannabis. It does not produce the “highness” caused by THC but interacts with the body’s endocannabinoid system; a network that regulates diverse physiological and cognitive processes.

The goals of the study are to determine 1) if CBD is safe and tolerable and whether it helps with the symptoms of ASD; 2) whether and how CBD alters neurotransmitters and/or improves brain connectivity; and 3) whether biomarkers of neuro-inflammation, also associated with ASD, are altered by CBD.

The clinical trial will consist of 30 children, ages eight to 12 years, with a confirmed diagnosis of moderate to severe autism. They must be free of other neurological conditions, such as epilepsy, and in general good health.

In the first phase of the study, half the children will receive an oral dose of CBD and half placebo. In the second phase, the groups will be switched and the half who originally received CBD will receive placebo, while the initial placebo group will receive CBD. Investigators will be blinded to which children are receiving which treatment until after all of the testing is completed at the end of the study.

For more information about the CMCR, click here.

For additional details about the study or to learn more about participating please visit ClinicalTrials.gov.